Celera Diagnostics to use Luminex' xMAP technology:
This article was originally published in Clinica
Alameda, California-based Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is to have worldwide, nonexclusive rights to develop and distribute in vitro diagnostic products based on Luminex' xMAP technology. Under the deal, Austin, Texas-based Luminex will gain royalties, as well as revenue from the sale of instruments and xMAP microspheres. "We believe the addition of Celera Diagnostics' future molecular tests to the growing list of commercial diagnostic assays can significantly expand the capabilities and acceptance of the Luminex xMAP technology," said Randy Marfin, vice-president of business development at Luminex.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.